title: Synergistic targeting with bone marrow-derived cells and PDGF improves diabetic vascular function.
abstract: Diabetes mellitus is associated with an increased risk of vascular disease, with significant alterations in systemic endothelial progenitor cells (EPCs) and peripheral vascular function. To identify the contribution of the different vascular compartments in the diabetic impairment of vascularization, we employed streptozotocin- and control-treated 3-mo-old C57Bl/6 mice in an isogeneic pinnal cardiac allograft model, revealing a significant delay in vascularization of wild-type cardiac tissue transplanted into diabetic mice. To investigate the basis of this impairment, the function of diabetic bone marrow cells was tested by transplantation of bone marrow cells isolated from diabetic and control mice into intact, unirradiated 18-mo-old C57Bl/6 mice, which have impaired function of both EPCs and peripheral endothelial cells. Importantly, cells derived from control, but not diabetic, bone marrow integrated into transplanted cardiac allografts. To assess the contribution of diabetic changes in the local vasculature, diabetic mice were treated with pinnal injections of platelet-derived growth factor (PDGF)-AB, which promotes cardiac angiogenesis in wild-type mice. However, whereas PDGF-AB enhanced allograft function in control mice, the activity of the cardiac transplants in the PDGF-AB-treated diabetic mice was significantly decreased. To decipher the potential interactions between systemic bone marrow-derived cells and local vascular pathways, diabetic mice were transplanted with wild-type bone marrow cells with or without PDGF-AB pinnal pretreatment, resulting in improved allograft function and donor cell recruitment only in the combination treatment arm. Overall, these studies show that the diabetic impairment in cardiac angiogenesis can be reversed by targeting the synergism between local trophic pathways and systemic cell function.
authors.affiliation: Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA.
authors.forename: David A
authors.initials: DA
authors.lastname: Klibansky
authors.forename: Andrew
authors.initials: A
authors.lastname: Chin
authors.forename: Inga J
authors.initials: IJ
authors.lastname: Duignan
authors.forename: Jay M
authors.initials: JM
authors.lastname: Edelberg
mesh_terms: D000818:Animals; D016026:Bone Marrow Transplantation / Q000379:methods*; D003925:Diabetic Angiopathies / Q000139:chemically induced / Q000503:physiopathology* / Q000628:therapy*; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000601:surgery*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010982:Platelet-Derived Growth Factor / Q000008:administration & dosage*; D013311:Streptozocin; D016896:Treatment Outcome
chemical_list: D010982:Platelet-Derived Growth Factor; C095477:platelet-derived growth factor AB; D013311:Streptozocin